Madhavi Rudraraju

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1

Thomas Boyer, Arun J. Sanyal, Florence Wong et al. · Gastroenterology · 2016 · 305 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

Mazen Noureddin, Mary E. Rinella, Naga Chalasani et al. · New England Journal of Medicine · 2025 · 91 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

Rohit Loomba, Pierre Bédossa, Katharine Grimmer et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH

Stephen A. Harrison, Naim Alkhouri, Grisell Ortiz‐Lasanta et al. · Journal of Hepatology · 2025 · 18 citations · Full text

Medicine, Internal Medicine, Pharmacology +11